Upadacitinib in psoriatic arthritis with prior TNF-inhibitor failure: a 56-week real-world study
Clin Exp Rheumatol. 2025; Advance online publication Epub ahead of print Doi: 10.55563/clinexprheumatol/gniy9i
Bakay et al. report that upadacitinib (UPA) demonstrated sustained efficacy across musculoskeletal and skin domains in PsA patients with prior inadequate response to TNF inhibitors, with a safety profile consistent with previous reports. Authors conducted a retrospective, single-centre observational study evaluating musculoskeletal disease activity, psoriasis, and patient-reported outcomes following initiation of UPA.
Improvements with UPA were observed across peripheral, axial, and entheseal domains, with no new safety signals identified. Findings add to existing data on JAK1 inhibition in treatment-experienced PsA and contribute to understanding outcomes in routine clinical practice.
Keywords:
